A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study Journal Article


Authors: Ross, R. W.; Galsky, M. D.; Scher, H. I.; Magidson, J.; Magidson, K.; Lee, G. S. M.; Katz, L.; Subudhi, S. K.; Anand, A.; Fleisher, M.; Kantoff, P. W.; Oh, W. K.
Article Title: A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study
Abstract: Background: Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer. Methods: Peripheral blood was prospectively collected from 62 men with castration-resistant prostate cancer on various treatment regimens who were enrolled in a training set at the Dana-Farber Cancer Institute (Boston, MA, USA) from August, 2006, to June, 2008, and from 140 patients with castration-resistant prostate cancer in a validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, USA) from August, 2006, to February, 2009. A panel of 168 inflammation-related and prostate cancer-related genes was assessed with optimised quantitative PCR to assess biomarkers predictive of survival. Findings: A six-gene model (consisting of ABL2, SEMA4D, ITGAL, and C1QA, TIMP1, CDKN1A) separated patients with castration-resistant prostate cancer into two risk groups: a low-risk group with a median survival of more than 34·9 months (median survival was not reached) and a high-risk group with a median survival of 7·8 months (95% CI 1·8-13·9; p<0·0001). The prognostic utility of the six-gene model was validated in an independent cohort. This model was associated with a significantly higher area under the curve compared with a clinicopathological model (0·90 [95% CI 0·78-0·96] vs 0·65 [0·52-0·78]; p=0·0067). Interpretation: Transcriptional profiling of whole blood yields crucial prognostic information about men with castration-resistant prostate cancer. The six-gene model suggests possible dysregulation of the immune system, a finding that warrants further study. Funding: Source MDX. © 2012 Elsevier Ltd.
Journal Title: Lancet Oncology
Volume: 13
Issue: 11
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2012-11-01
Start Page: 1105
End Page: 1113
Language: English
DOI: 10.1016/s1470-2045(12)70263-2
PROVIDER: scopus
PUBMED: 23059047
DOI/URL:
Notes: --- - "Export Date: 3 December 2012" - "CODEN: LOANB" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sumit Kumar Subudhi
    11 Subudhi
  2. Howard Scher
    1130 Scher
  3. Aseem Anand
    61 Anand